Introduction: Tigecycline is an antibiotic belonging to the glycylcyclines class with in vitro activity against most gram positive bacteria, even multidrug resistant pathogens. It is considered to be a newer treatment option for emerging multidrug resistant pathogens.
Aims & Objectives: To evaluate the in vitro activity of Tigecycline against Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) isolated from various clinical specimens to compare with other antimicrobials.
Materials & Methods: A total of 75 multidrug resistant isolates of MRSA (60) and VRE (15) were tested for Tigecycline susceptibility by the E-test and disc diffusion methods.
Results: Tigecycline showed good microbiological activity against all the isolates of MRSA and VRE with 100% susceptibility.
Conclusion: Tigecycline was found to be highly effective against multidrug resistant MRSA & VRE. Therefore it is an alternative option for treatment of complicated skin &soft tissue and intra-abdominal infections caused by such multidrug resistant pathogens.